BriaCell Therapeutics (BCTX) announces a clinical supply agreement with BeiGene (BGNE) to evaluate the safety and efficacy of Bria-OTS, BriaCell’s next generation immunotherapy, in combination with BeiGene’s anti-PD-1 antibody, tislelizumab, for the treatment of advanced heavily pretreated metastatic breast cancer. “We are extremely excited about partnering with BeiGene on this novel immunotherapy approach with planned expansion to prostate and other cancers,” stated Dr. William Williams, BriaCell’s President & CEO. “This agreement marks another positive milestone for BriaCell in our commitment to transform cancer care.” The limited access Phase 1/2 clinical trial will initially evaluate the safety and efficacy of Bria-OTS alone in breast cancer and later in combination with tislelizumab. BriaCell also plans to evaluate Bria-OTS in prostate and other cancers.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell’s Breakthrough in Advanced Breast Cancer
- BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
- BriaCell announces data on Bria-IMT to be presented at ASCO 2024
- BriaCell Therapeutics Secures $5M in Funding
- BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering